TScan Therapeutics (TCRX)
(Delayed Data from NSDQ)
$7.27 USD
+0.09 (1.25%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $7.13 -0.14 (-1.93%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TCRX 7.27 +0.09(1.25%)
Will TCRX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TCRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TCRX
Strength Seen in Zealand Pharma AS (ZLDPF): Can Its 11.6% Jump Turn into More Strength?
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates
TCRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
TScan Therapeutics, Inc. (TCRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Tops Revenue Estimates
Other News for TCRX
TScan Therapeutics Announces Updates to its Board of Directors
Leadership Changes and Stockholder Decisions at TScan Therapeutics
TScan Therapeutics appoints Nicholson to board of directors, Biggar as Chair
The Analyst Landscape: 7 Takes On TScan Therapeutics
Innovative Cancer Therapy Approach Solidifies Buy Rating for TScan Therapeutics